Table 1 –
Clinical and pathological characteristics of the study cohort (n=217) stratified by the absence and presence of metastatic disease at the time of nephrectomy
| Variable* | Overall (n=217) | Locoregional disease (n=112) | Metastatic disease (n=105) | p |
|---|---|---|---|---|
| Age in years | 61 (52, 69) | 62 (53, 70) | 60 (52, 68) | 0.3 |
| Sex | 0.6 | |||
| Female | 52 (24%) | 29 (26%) | 23 (22%) | |
| Male | 165 (76%) | 83 (74%) | 82 (78%) | |
| BMI | 28.5 (24.7, 31.6) | 28.5 (25.5, 31.8) | 28.4 (24.0, 31.6) | 0.3 |
| Smoking Status (n=212) | 0.5 | |||
| Current | 20 (9%) | 13 (12%) | 7 (7%) | |
| Former | 100 (47%) | 50 (45%) | 50 (50%) | |
| Never | 92 (43%) | 48 (43%) | 44 (44%) | |
| KPS (n=94)** | NA | |||
| ≥ 80 | 81 (86%) | NA | 81 (86%) | |
| < 80 | 13 (14%) | NA | 13 (14%) | |
| Tumor Histology | 0.6 | |||
| ccRCC | 164 (76%) | 87 (78%) | 77 (73%) | |
| non-ccRCC | 53 (24%) | 25 (22%) | 28 (27%) | |
| Tumor Size in cm | 9.4 (6.5, 12) | 8.0 (5.5, 10.7) | 10.0 (7.5, 12.5) | <0.001 |
| T Stage Group (n=214) | 0.002 | |||
| T1/T2 | 45 (21%) | 33 (30%) | 12 (12%) | |
| T3/T4 | 169 (79%) | 78 (70%) | 91 (88%) | |
| N Stage | 0.002 | |||
| N0/ Nx | 169 (78%) | 97 (87%) | 72 (69%) | |
| N1/ N2 | 48 (22%) | 15 (13%) | 33 (31%) | |
| WBC count (103/μL) | 7.80 (6.50, 9.50) | 7.40 (6.10, 9.15) | 8.10 (6.80, 10.10) | 0.007 |
| RBC count (106/μL) | 4.43 (4.01, 4.74) | 4.43 (4.04, 4.72) | 4.41 (3.98, 4.75) | 0.7 |
| PLT count (n=214, 103/μL) | 311 (234, 420) | 281 (224, 407) | 343 (253, 422) | 0.004 |
| Absolute Neutrophils count (103/μL) | 5.40 (4.30, 7.00) | 5.10 (3.90, 6.43) | 5.77 (4.60, 7.60) | <0.001 |
| Absolute Lymphocytes count (103/μL) | 1.40 (1.10, 1.80) | 1.50 (1.17, 1.90) | 1.40 (1.10, 1.70) | 0.084 |
| Absolute Monocytes count (103/μL) | 0.50 (0.40, 0.70) | 0.50 (0.30, 0.60) | 0.50 (0.40, 0.70) | 0.009 |
| NLR | 3.82 (2.90, 5.40) | 3.29 (2.50, 4.44) | 4.31 (3.31, 6.08) | <0.001 |
| LMR | 2.86 (2.00, 4.00) | 3.23 (2.25, 4.21) | 2.60 (1.62, 3.50) | <0.001 |
| PLR (n=214) | 216 (161, 316) | 194 (146, 274) | 248 (175, 344) | <0.001 |
| Median post-op NLR (n=89)** | 4.4 (3.1,6.3) | NA | 4.4 (3.1,6.3) | NA |
| Minimum post-op NLR (n=89)** | 3.25 (2.33,5.27) | NA | 3.25 (2.33,5.27) | NA |
| Median post-op NLR % Change Groups (n=89)** | NA | |||
| >25% Decrease | 21 (24%) | NA | 21 (24%) | |
| >25% Increase | 27 (30%) | NA | 27 (30%) | |
| No Change | 41 (46%) | NA | 41 (46%) | |
| Minimum post-op NLR % Change Groups (N=89)** | NA | |||
| >25% Decrease | 40 (45%) | NA | 40 (45%) | |
| >25% Increase | 12 (13%) | NA | 12 (13%) | |
| No Change | 37 (42%) | NA | 37 (42%) | |
BMI = body mass index; KPS = Karnofsky performance status; ccRCC = clear cell renal cell carcinoma; WBC = white blood cell; RBC = red blood cell; PLT = platelets; NLR = neutrophil-lymphocyte ratio; LMR = lymphocyte-monocyte ratio; PLR = platelet-lymphocyte ratio; NA = not applicable.
*
Continuous variables are reported as median and inter-quartile range and categorical ariables are reported as number and percent.
**
Only included for patients with metastatic disease.